Ask about this productRelated genes to: LGALS9 Blocking Peptide
- Gene:
- LGALS9 NIH gene
- Name:
- galectin 9
- Previous symbol:
- -
- Synonyms:
- LGALS9A
- Chromosome:
- 17q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-06-25
- Date modifiied:
- 2016-05-13
Related products to: LGALS9 Blocking Peptide
Related articles to: LGALS9 Blocking Peptide
- Immunotherapeutic approaches for cutaneous squamous cell carcinoma (cSCC) remain limited to programmed cell death protein 1 (PD-1) blockade. Although genomics studies have characterized key driver mutations in cSCC, preclinical models that faithfully recapitulate both the genetic landscape and immune microenvironment of the human disease, that could drive the development of novel, effective therapies, are lacking. - Source: PubMed
Publication date: 2026/08/13
Rodriguez Rosario Alanis ERangel RobertoBalbin NicholasNizami Zohra NHadi JaafarNoor AhmedDong LipingCorona ArnoldoBhavani NikithaCruz Sanchez Ricardo MSunga Gemalene MVeeramachaneni RatnaManyam Ganiraju CWang JingYu WendongSikora Andrew GN Myers JeffreyRangel Roberto - Lung cancer (LC) is a leading cause of cancer-related death. Microwave ablation (MWA) is a promising local therapy, but its impact on systemic immunity remains unclear. - Source: PubMed
Publication date: 2026/07/30
Wu YuesongWei XiaolongYang WentaoWang FengpingWang JianchunHuang ZhiZou FengxiangLiu Jianqun - The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance. - Source: PubMed
Publication date: 2026/08/03
Wang QianyuTian NaGuo HanchuanXiang YingshiXiao YiLin GuoleZhang GuannanXu LaiLu JunyangChen GangCai HuiyunDu XiaohuiDu JunfengWu Bin - We aimed to investigate whether LGALS9 contributes to the effects of repetitive transcranial magnetic stimulation (rTMS) in the treatment of ischemic stroke (IS) in rats. - Source: PubMed
Publication date: 2026/04/28
Huang JinlianWu JunHuang LishanWu Xia - Introduction Galectin-9, a β-galactoside-binding protein, is elevated in various kidney diseases. While exogenous galectin-9 attenuates kidney injury in experimental models, it remains unclear whether endogenous plasma galectin-9 reflects renal histopathology and independently predicts long-term adverse outcomes in chronic kidney disease (CKD). Methods Plasma galectin-9 levels were prospectively measured in 366 participants from the Taipei Renal Transcriptomics and Outcomes Investigation (TRTOI) cohort. Renal histopathology and chronicity were assessed using a modified Mayo Clinic Chronicity Score (MCCS). Major adverse renal events (MAREs) were defined as ≥40% decline in eGFR, kidney failure, or death. Findings were validated in 549 participants from the Boston Kidney Biopsy Cohort (BKBC). In vitro, mouse mesangial cells (SV40-MES-13) were used to evaluate galectin-9 effects on TGF-β-induced mesangial activation. Results Transcriptomic analysis showed upregulation of LGALS9 (encoding galectin-9) in fibrotic kidneys. Plasma galectin-9 positively correlated with urine protein-to-creatinine ratio and MCCS, and inversely with eGFR. Elevated galectin-9 was independently associated with mesangial expansion. In vitro, exogenous galectin-9 attenuated TGF-β-induced mesangial cell activation, proliferation, and profibrotic responses; these effects were reversed by lactose, a competitive inhibitor of the carbohydrate recognition domains of galectin-9. In the TRTOI cohort, participants in the highest galectin-9 tertile had a significantly increased risk of MAREs, independent of confounders. Validation in the BKBC cohort confirmed that higher galectin-9 levels were independently associated with increased all-cause mortality. Conclusion Elevated plasma galectin-9 is associated with mesangial expansion and predicts a higher risk of MAREs in patients with CKD. - Source: PubMed
Publication date: 2026/07/29
Tsai Ming-TsunLi Szu-YuanKim DonggunPark JihwanSchmidt Insa MZhao RunqiWaikar Sushrut SHsieh Tsung-HanYang HaichunChen Tz-HengOu Shuo-MingYang Ruey-Bing